The 14th JFCR−ISCC
In Memory of Dr. Takashi Tsuruo

December 2-3, 2009
Hotel Nikko Tokyo, Tokyo

We would like to ask your participation in the 14th Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy, which will be held on December 2 (Wed) and 3 (Thu), 2009, in Hotel Nikko Tokyo, Daiba, Tokyo, Japan.
Recently many international co-operative studies are ongoing for the development of new antitumor agents. We believe that such world-wide, harmonized study should become much more important in the future. Under this circumstance, we are organizing a series of international symposia entitled "International Symposium on Cancer Chemotherapy". The purpose of the symposium is to discuss recent progress in the development of new antitumor agents and future perspectives in cancer chemotherapy. The Symposia were successfully held in Tokyo in 1996-2008 with about 300-350 participants. It is hoped that the Symposium will both encourage international cooperation in cancer chemotherapy and stimulate workers in Japan.
We are looking forward to seeing you in the Symposium.

Executive Committee
Ryuzo Ueda (Nagoya City Univ.)
Saburo Sone (Tokushima Univ.)
Kiyohiko Hatake (Cancer Chemotherapy Ctr)
Yoshikazu Sugimoto (Keio Univ.)

December 2, 2009 (Wednesday)

Welcome and Introduction

10:00-10:10

Ryuzo Ueda (Nagoya City University, Nagoya)

Session I : Dr. Tsuruo's work and beyond (I): Drug resistance and new drugs

Chairperson: Saburo Sone (Tokushima University, Tokushima)

10:10-10:30

Mikihiko Naito (National Institute of Health Science, Tokyo)

Drug resistance and apoptosis of cancer cells

10:30-10:50

Yoshikazu Sugimoto (Keio University, Tokyo)

Multidrug resistance by P-glycoprotein and BCRP

10:50-11:10

Takao Yamori (Cancer Chemotherapy Center, Tokyo)

A new PI3 kinase inhibitor ZSTK474 identified by JFCR39 cancer cell lines panel

11:10-11:30

Coffee Break

Session II : Dr. Tsuruo's work and beyond (II): New targets for molecular therapy

Chairperson: Mitsuaki Yoshida (Cancer Chemotherapy Center, Tokyo)

11:30-11:50

Akihiro Tomida (Cancer Chemotherapy Center, Tokyo)

Unfolded protein response in tumor microenvironment

11:50-12:10

Naoya Fujita (Cancer Chemotherapy Center, Tokyo)

Molecular mechanisms of pulmonary metastasis induced by a tumor cell surface Aggrus protein

12:10-12:30

Hiroyuki Seimiya (Cancer Chemotherapy Center, Tokyo)

Telomere maintenance systems as anticancer targets

12:45-13:15

(Committee Meeting)

Session III : New strategies with anticancer drugs

Chairpersons: Jaap Verweij (Erasmus University Medical Center, Rotterdam)
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)

13:30-14:05

Bruce A Chabner (MGH Cancer Center, Boston)

Genomically guided early drug development

14:05-14:30

Shinichi Akiyama (Kagoshima University, Kagoshima)

Molecular basis for the antiangiogenic effect of 5-FU and tegafur

14:30-15:05

Mark J Ratain (University of Chicago, Chicago)

Genome-wide pharmacogenetic studies

15:05-15:15

Discussion

15:15-15:35

Coffee Break

Special Lecture I

Chairperson: Michihiko Kuwano (Kyushu University, Fukuoka)

15:35-16:15

Victor Ling (BC Cancer Research Center, Vancouver)

ABC transporters and multidrug resistance

Session IV: Antibody therapies and ALK inhibitors

Chairpersons: David R. Newell (University of Newcastle upon Tyne, Newcastle)
Tomoki Naoe (Nagoya University, Nagoya)

16:15-16:40

Ryuzo Ueda (Nagoya City University, Nagoya)

Antibody therapy of lymphoma and beyond

16:40-17:05

Toshihiko Doi (National Cancer Center Hospital East, Kashiwa)

Targeting the TRAIL receptor pathway

17:05-17:40

Mace Rothenberg (Pfizer)

IGF-1R and ALK: promising new targets in the treatment of non-small cell lung cancer

17:40-17:50

Discussion

December 3, 2009 (Thursday)

VKinase inhibitors and prognostic/predictive factors

Chairpersons: Robert H. Shoemaker (NCI-FCRDC, Frederick)
Yoshikazu Sugimoto (Keio University, Tokyo)

09:30-09:55

Seiji Yano (Kanazawa University, Kanazawa)

HGF/MET as a therapeutic target for EGFR-TKI resistant lung cancer harboring EGFR mutations

09:55-10:30

Manuel Hidalgo (Centro Integral Oncológico Clara Campal, Madrid)

IGFR Inhibitors

10:30-10:55

Nagahiro Saijo (Kinki University School of Medicine, Osaka)

Prognostic/predictive factors for cancer chemotherapy

10:55-11:05

Discussion

11:05-11:25

Coffee Break

Special Lecture II

Chairperson: Yoshiro Niitsu (Sapporo Medical University, Sapporo)

11:25-12:05

Yusuke Nakamura (University of Tokyo, Tokyo)

Cancer vaccine therapy

Luncheon Seminars

12:15-13:15

Seminar I Sponsored by Chugai Pharmaceutical Co., Ltd and EFPIA

Chairperson: Tomohide Tamura (National Cancer Center Hospital, Tokyo)

Manuel Hidalgo (Centro Integral Oncológico Clara Campal, Madrid)

Emerging new therapeutics in lung cancer

Seminar II Sponsored by AstraZeneca K.K. and PhRMA

Chairperson: Toshi-hiko Kobayashi (PhRMA, Tokyo)

Qunsheng Ji (AstraZeneca, Innovation Center China)

New targets and new drugs for oncology - challenges from translational science perspective

Session VI: Molecular targets and combination therapies

Chairpersons: Mark J Ratain (University of Chicago, Chicago)
Kazuto Nishio (Kinki University School of Medicine, Osaka)

13:30-14:05

Jaap Verweij (Erasmus University Medical Center, Rotterdam)

Combining targeted agents with (non)targeted agents: Potentials, pitfalls, and early clinical trial design

14:05-14:40

Ann-Lii Cheng (National Taiwan University Hospital, Taipei)

Chemotherapy and molecular target therapy for hepatocellular carcinoma

14:40-15:05

Atsushi Ohtsu (National Cancer Center Hospital East, Kashiwa)

New era with molecular targeting agents for gastric cancer

15:05-15:15

Discussion

15:15-15:30

Coffee Break

Session VII: New targets and new drugs

Chairpersons: Victor Ling (BC Cancer Research Center, Vancouver)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)

15:30-16:05

Robert H. Shoemaker (NCI-FCRDC, Frederick)

Therapeutic targeting of alveolar soft part sarcoma

16:05-16:30

Qunsheng Ji (AstraZeneca)

Title TBA

16:30-17:05

David R. Newell (University of Newcastle upon Tyne, Newcastle)

Targeting DNA repair pathways

17:05-17:15

Discussion

Closing Remark

17:15-17:25

Bruce A Chabner (MGH Cancer Center, Boston)

For further information

please contact:
Masako Sasaki
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-10-6, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3520-0111 (ex. 5413) FAX: 81-3-3570-0482

Page TOP